Sodium-glucose Cotransporter 2 Inhibitors in Patients with Type 2 Diabetes and Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis

Overview

Journal Am J Prev Cardiol

Date 2025 Jan 27

PMID 39867488

Authors

Huzaifa Ul Haq Ansari

Muhammad Ammar Samad

Eman Mahboob

Eeshal Zulfiqar

Shurjeel Uddin Qazi

Areeba Ahsan

Mushood Ahmed

Faizan Ahmed

Raheel Ahmed

Shafaqat Ali

Mahboob Alam

Jamal S Rana

Gregg C Fonarow

Affiliations

Soon will be listed here.

Abstract

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown benefits in improving cardiovascular (CV) outcomes in patients with heart failure (HF) and may mitigate symptom progression in myocardial infarction (MI). However, their effectiveness in patients with type 2 diabetes and MI undergoing percutaneous coronary intervention (PCI) is unclear.

Methods: To identify eligible studies, a comprehensive search of electronic databases, PubMed, Cochrane Library, Scopus and Embase, was conducted from inception until May 2024. Results were presented as risk ratios (RR) and their corresponding 95 % confidence intervals (CIs).

Results: Our analysis included 8 observational studies comprising 24,229 patients. The results indicated that SGLT2i with PCI was associated with a significantly reduced risk of all-cause death (RR=0.61; 95 % CI=0.54 to 0.68), CV death (RR=0.46; 95 % CI=0.22 to 0.94), major adverse cardiovascular events (RR=0.80;95 % CI: 0.66 to 0.96), HF-related hospitalizations (RR=0.63; 95 % CI=0.44 to 0.90), stroke (RR=0.77; 95 % CI: 0.62 to 0.96) and acute kidney injury (RR=0.46; 95 % CI: 0.25 to 0.84) compared to PCI without SGLT2i use. However, the risk of revascularization remained comparable between the groups.

Conclusion: Our study demonstrates that SGLT2i with PCI in patients with type 2 diabetes and MI are associated with improved CV outcomes compared to PCI without SGLT2i use. Randomized controlled trials are required to confirm the improvement in outcomes with SGLT2i therapy combined with PCI in patients with MI and diabetes.

References

Jiang K, Xu Y, Wang D, Chen F, Tu Z, Qian J . Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. Protein Cell. 2021; 13(5):336-359. PMC: 9008115. DOI: 10.1007/s13238-020-00809-4. View

Lee H, Chan Y, Chuang C, Li P, Yeh Y, Hsiao F . Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors. Eur Heart J Cardiovasc Pharmacother. 2023; 9(4):301-310. DOI: 10.1093/ehjcvp/pvad004. View

Lopaschuk G, Verma S . Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020; 5(6):632-644. PMC: 7315190. DOI: 10.1016/j.jacbts.2020.02.004. View

Butler J, Jones W, Udell J, Anker S, Petrie M, Harrington J . Empagliflozin after Acute Myocardial Infarction. N Engl J Med. 2024; 390(16):1455-1466. DOI: 10.1056/NEJMoa2314051. View

Vallon V, Verma S . Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. Annu Rev Physiol. 2020; 83:503-528. PMC: 8017904. DOI: 10.1146/annurev-physiol-031620-095920. View

Sterne J, Hernan M, Reeves B, Savovic J, Berkman N, Viswanathan M . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355:i4919. PMC: 5062054. DOI: 10.1136/bmj.i4919. View

Gamaza-Chulian S, Diaz-Retamino E, Gonzalez-Teston F, Gaitero J, Castillo M, Alfaro R . Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study. BMC Cardiovasc Disord. 2021; 21(1):456. PMC: 8456580. DOI: 10.1186/s12872-021-02250-9. View

Benjamin E, Virani S, Callaway C, Chamberlain A, Chang A, Cheng S . Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018; 137(12):e67-e492. DOI: 10.1161/CIR.0000000000000558. View

Sattar N, McLaren J, Kristensen S, Preiss D, McMurray J . SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. Diabetologia. 2016; 59(7):1333-1339. PMC: 4901113. DOI: 10.1007/s00125-016-3956-x. View

10.

Cherney D, Perkins B, Soleymanlou N, Maione M, Lai V, Lee A . Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2013; 129(5):587-97. DOI: 10.1161/CIRCULATIONAHA.113.005081. View

11.

Ito M, Tanaka T . The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors. Intern Med. 2018; 57(15):2105-2114. PMC: 6120824. DOI: 10.2169/internalmedicine.9842-17. View

12.

Reed G, Rossi J, Cannon C . Acute myocardial infarction. Lancet. 2016; 389(10065):197-210. DOI: 10.1016/S0140-6736(16)30677-8. View

13.

Al Jobori H, Daniele G, Adams J, Cersosimo E, Triplitt C, DeFronzo R . Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. Diabetes Obes Metab. 2017; 19(6):809-813. DOI: 10.1111/dom.12881. View

14.

Kim J, Lyu Y, Kim B, Kim M, Kim S, Baek K . Cardiorenal outcomes and mortality after sodium-glucose cotransporter-2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history. Diabetes Obes Metab. 2024; 26(7):2567-2577. DOI: 10.1111/dom.15565. View

15.

Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Bonaca M . SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018; 393(10166):31-39. DOI: 10.1016/S0140-6736(18)32590-X. View

16.

Paolisso P, Bergamaschi L, Gragnano F, Gallinoro E, Cesaro A, Sardu C . Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry. Pharmacol Res. 2022; 187:106597. PMC: 9946774. DOI: 10.1016/j.phrs.2022.106597. View

17.

Nikolic M, Zivkovic V, Jovic J, Sretenovic J, Davidovic G, Simovic S . SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms. Heart Fail Rev. 2021; 27(3):935-949. DOI: 10.1007/s10741-021-10079-9. View

18.

Adel S, Jorfi F, Mombeini H, Rashidi H, Fazeli S . Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention. Saudi Med J. 2022; 43(5):458-464. PMC: 9280595. DOI: 10.15537/smj.2022.43.5.20220018. View

19.

Cai D, Chen Q, Mao L, Xiao T, Wang Y, Gu Q . Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients. Eur J Clin Pharmacol. 2024; 80(4):613-620. PMC: 10937750. DOI: 10.1007/s00228-024-03623-7. View

20.

Batzias K, Antonopoulos A, Oikonomou E, Siasos G, Bletsa E, Stampouloglou P . Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis. J Diabetes Res. 2019; 2018:1232583. PMC: 6304901. DOI: 10.1155/2018/1232583. View